Skip to main content

Table 2 Treatment outcomes for participants finishing follow-up as part of therapeutic efficacy monitoring in Guinea, 2016 (N = 413)

From: Efficacy and safety of artesunate–amodiaquine and artemether–lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial

 

Maferinyah

Labé

ASAQ

AL

ASAQ

AL

Enrolled

107

104

105

105

Reached study outcome

105

101

104

103

Treatment failure

5 (5)

8 (8)

3 (3)

6 (6)

 Early treatment failure

0

0

0

0

 Late treatment failure

5 (5)

8 (8)

3 (3)

6 (6)

Recrudescence

0

0

1 (1)

1 (1)

Day 28

0

0

1 (1)

1 (1)

Reinfection

5 (5)

8 (8)

2 (2)

5 (5)

 Day 21

1 (1)

3 (3)

1 (1)

1 (1)

 Day 28

4 (4)

5 (5)

1 (1)

4 (4)

Adequate clinical and parasitological response

100 (95)

93 (92)

101 (97)

97 (94)

Kaplan–Meier Day 28 efficacy

 Uncorrected

95.2% (91.3–99.4)

92.1% (87.1–97.5)

97.1% (94–100)

94.2% (89.9–98.8)

 Microsatellite-corrected

100%a

100%a

99% (97.2–100)

99% (97.1–100)

  1. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, 28-day follow-up
  2. aconfidence intervals: undefined